Cognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
Cognition Therapeutics received a second philanthropic donation from Jeffrey Pechter, extending the ongoing expanded access program (EAP) for zervimesine to two years of treatment for participants. The EAP, which has enrolled 32 individuals, provides 100 mg of once-daily oral zervimesine, an investigational therapy designed to protect synaptic function in patients with neurodegenerative diseases. James E. Galvin, MD, MPH, lead investigator for the EAP, noted that the program offers access to an experimental medication for former SHIMMER study participants and others who meet the EAP’s eligibility criteria.
Key figures
- Eap dose
- 100 mg once-daily
- Eap duration
- two years
- Eap participants
- 32
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.